Table 1.
Comparison of BeFree performance to previous work
| Method | Drug-disease | Gene-disease | Drug-target |
|---|---|---|---|
| Chun et al. 2006 [25] | - | 83% | - |
| Bundschus et al. 2008 [13] | - | 78% | - |
| Gurulingappa et al. 2012 [11] | 87% | - | - |
| Kang et al. 2014 [12] | 54% | - | - |
| Névéol and Lu. 2010 [10] | - | - | 69% |
| Xu and Wang 2012 [6] | - | - | 40% |
| Xu and Wang 2013 [43] | 23% | - | - |
| Hakenberg et al. 2012 [15] | 76% | 84% | 83% |
| Buyko et al. 2012 [42] | 79% | 76% | 82% |
| BeFree | 79% | 85% | 83% |
Performance of different approaches including BeFree in terms of F for the three association types is presented. Note that the results corresponding to the work of others are quoted verbatim from the literature, and are therefore not directly comparable.